stichd to Become Official Merchandise Partner of Aston Martin Aramco Cognizant Formula One® Team
7.6.2023 11:00:00 EEST | Business Wire | Press release
Global licensing partner stichd has signed a long-term agreement with the Aston Martin Aramco Cognizant Formula One® Team (AMF1 Team), which gives it the exclusive rights to design, produce and distribute the group’s fanwear products starting in 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005415/en/
Global licensing partner stichd has signed a long-term agreement with the Aston Martin Aramco Cognizant Formula One® Team (AMF1 Team), which gives it the exclusive rights to design, produce and distribute the group’s fanwear products starting in 2024. (Graphic: Business Wire)
stichd, part of the PUMA Group, will gain global distribution rights to sell AMF1 Team’s branded apparel and accessories for men, women and kids across several online and offline channels. It will also become the official e-commerce partner of the team.
“We are beyond excited to join forces with AMF1 Team,” said Nina Nix, CEO of stichd. “As F1® and Aston Martin continue to grow its momentum, we are ready to translate this passion into fashion-forward apparel and accessories. And we really look forward to doing this with the AMF1 team.”
stichd, a company for licensed fanwear and lifestyle apparel as well as legwear, bodywear and swimwear, will make AMF1 Team’s official merchandise available on amf1.com, the Fuel for Fans online store and other online and offline stores.
“We really feel the passion and intensity of our fans,” said Jefferson Slack, AMF1 Team Managing Director, Commercial & Marketing. “This year, we’ve witnessed huge growth in our audience – particularly as the team’s on-track performances have improved. A lot of what we do as a team is directed towards surprising and delighting our fanbase. Partnering with stichd to make official fanwear available to everyone is a fantastic opportunity, and we look forward to working closely with them on next year’s first collection.”
Starting in 2024, stichd will also have the exclusive rights to operate the fan retail stores during every Formula One® race weekend. At these stores, stichd will sell Formula One® products as well as team replica, fanwear, and special-edition collections – including AMF1 fanwear, teamwear, drivers’ specials and replica versions of the team kit.
stichd’s parent company PUMA is the leading provider of race gear for drivers, teamwear and merchandise products in Formula One® and other motorsport series.
The first products of stichd’s new partnership with AMF1 will be available at the start of the 2024 FIA Formula One World Championship season.
About stichd
stichd is a trusted brand partner with its head office located in ‘s-Hertogenbosch, Netherlands. Employing over 700 people, the company’s current brand partners include: PUMA, Tommy Hilfiger, Levi’s, Head, Calvin Klein, Mercedes-AMG Petronas Formula One Team, Scuderia Ferrari, Porsche Motorsport, Ayrton Senna, Formula 1, Formula E, BMW Lifestyle and Motorsport and Manchester City Football Club. From branded socks and underwear to fashionable swimwear, fanwear and lifestyle apparel and accessories, stichd is proud to make products that are universal and personal to everyone. At stichd, products are seen as humble heroes -pieces that are intimate and prized by many. By partnering with an array of global A-list brands, stichd makes exceptional products for a global audience; striking a balance between understanding the multiple brands and markets, while making products people love. With the mission to Consciously Craft Convenience, stichd is continuously innovating, remaining a leader in fashion essentials, fanwear and lifestyle. For more information, please visit www.stichd.com
About Aston Martin Aramco Cognizant Formula One® Team
The legendary Aston Martin marque first raced in Formula One in 1959 and returned to the sport in 2021 under the leadership of Canadian entrepreneur Lawrence Stroll. With a team of passionate people at its heart, and a talented squad of drivers – including double World Champion Fernando Alonso and Canada’s Lance Stroll – this is a team with both a rich heritage and a fresh perspective. Alongside collaborative and strategic partners, the Silverstone-based team is bringing new energy to the sport with a determination to shake up the order and compete at the sharp end.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230607005415/en/
Contact information
Media Contact stichd: Bart Speet | bart.speet@stichd.com
Media Contact AMF1: Steve Cooper | stephen.cooper@astonmartinf1.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom